The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
FDA approves Spravato as the first monotherapy for adults with major depressive disorder unresponsive to two oral ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Spravato is the first and only approved monotherapy for adults with refractory major depressive disorder. Approval of ...
(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...
so FDA approval will lead to a safer, more well-regulated control and use of this medication in clinical practice for patients with major depressive disorder.” “Given the reality that ...